EGFR and neoplasm: For example, one patient had a PTPN11 mutation thought to drive EGFR addiction and, hence, response to afatinib, and another patient had a tumor that was EGFR amplified and carried an additional allele on the amplicon, potentially underlying the sustained response observed [46].